Results 101 to 110 of about 1,334 (146)

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes. [PDF]

Sci Rep
Murao F, Yanai R, Kusuhara S, Abe Y, Shimura M, Ohara H, Terasaki H, Sugimoto M, Matsubara H, Hirano Y, Kinoshita T, Tsujinaka H, Seki K, Iwase T, Mitamura Y, J-CREST.   +15 more
europepmc   +1 more source

Comparisons of Early Changes of Vascular Structure After Treatment with Faricimab and Aflibercept in Eyes with Macular Neovascularization by OCT Angiography. [PDF]

Clin Ophthalmol
Chujo S, Matsubara H, Mase Y, Muramoto Y, Kato K, Kondo M.   +5 more
europepmc   +1 more source

The Implementation of Faricimab in East Lancashire NHS Trust: Highlighting the Real-World Efficacy and Safety in Patients With Neovascular Age-Related Macular Degeneration. [PDF]

Cureus
Lloyd A, Elbalawi M, Kurc M, Hussain M, Abugreen S.   +4 more
europepmc   +1 more source

Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials. [PDF]

Ophthalmol Ther
Friedman SM, Xu Y, Sherman S, Kuznik A, Mojebi A, Keeping S, Chan K, Leng T, Patel N.   +8 more
europepmc   +1 more source

Association of Molar Dose and Early Retinochoroidal Blood Flow Changes After Intravitreal Anti-Vascular Endothelial Growth Factor Therapy. [PDF]

Invest Ophthalmol Vis Sci
Kato N, Haruta M, Arai R, Nagae A, Sato K, Furushima K, Yoshida S.   +6 more
europepmc   +1 more source

Extended Real-World Efficacy of Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: 9-Month Follow-Up Results. [PDF]

J Clin Med
Hafner M, Herold TR, Kufner A, Eckardt F, Asani B, Priglinger SG, Schiefelbein J.   +6 more
europepmc   +1 more source

A prospective, open-label, single-arm, investigator-initiated clinical trial to assess the efficacy, safety and durability of faricimab in patients with inadequate response to current treatment for neovascular age-related macular degeneration: protocol design and rationale for the FURGGHORN Study. [PDF]

BMJ Open Ophthalmol
Phan LT, Hong T, Chang JH, Mehta H, Fraser-Bell S, Cheung GCM, Broadhead GK, Chang AA.   +7 more
europepmc   +1 more source

Switching from Aflibercept to Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration: Short-Term Results from Real-Life Study. [PDF]

J Clin Med
Kucharczuk J, Kasprzak H, Gawęcki M.
europepmc   +1 more source

A multicenter, single-arm study using a modified faricimab treat-and-extend regimen in patients with macular edema due to central retinal vein occlusion: RVOSTAR study design protocol. [PDF]

PLoS One
Kondo M, Shimura M, Tsujikawa A, Muraoka Y, Kogo T, Akiyama Y, Hama Y, Tsujimura J, Iwasaki K, Kamei M.   +9 more
europepmc   +1 more source

Real-World Efficacy of Intravitreal Faricimab for Macular Edema Secondary to Retinal Vein Occlusion: Short-Term Outcomes and Optical Coherence Tomography Biomarker Analysis. [PDF]

Clin Ophthalmol
Inokuchi S, Mizuki Y, Kamata A, Onishi J, Hayashi T, Mizuki N.   +5 more
europepmc   +1 more source